| Price and Chart delayed at least 15 mintues. |
|
Price
$ 54.95
|
Change
0.00
|
|
Open
0.00
|
% Change
0.0%
|
|
Prev Close
54.95
|
Volume
NA
|
|
Market Value
28 bil
|
P/E Ratio
17.5
|
|
Bid
53.46
|
EPS
3.14
|
|
Ask
0.00
|
Dividend
0.78
|
|
High
0.00
|
Yield
1.4
|
|
Low
0.00
|
Shares Out
513 mil
|
|
52wk High
66.99
|
52wk Low
41.35
|
|
Industry: Drug Manufacturers - Other
|
|
Sector: Healthcare
|
NVO Profile
A healthcare company, which is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has two business segments: diabetes care and biopharmaceuticals.
Novo Nordisk A/S
Novo Alle
DK-2880 Bagsvaerd,
Phone: (454) 444-8888
Fax: (454) 449-0555
Web Site: www.novonordisk.com
NVO Wires Headlines
|
|
| 06.26.09 |
|
Danish cos. pay $8.4 million from Iraq scheme
|
|
| 06.13.09 |
|
Novo Nordisk warns patients about stolen insulin
|
|
| 06.09.09 |
|
Amylin, Eli Lilly see no rise in Byetta heart risk
|
More NVO From Wires Headlines >
Forbes.com on NVO RSS
No news found in the past 30 days.NVO Press Releases
|
| |
No press releases found in the past 30 days. |
More NVO Press Releases >
NVO Ratios & Returns
| Price-to-sales |
4.08 |
| Return on Equity |
29.2 |
| Operating Margin |
31.3 |
| Profit Margin |
21.2% |
More NVO Ratios & Returns >
NVO Financials
| Sales |
$8.537 bil |
| Profits |
$1.807 bil |
| Assets |
$9.483 bil |
| Employees |
27068.0 |
|
|
|
Novo Nordisk is ranked # 500 on the 2009 Forbes 2000 List
|
|
Thomson / IBES Earnings Estimates on NVO
Accounting Risk
Buy/Hold/Sell Analysis
Forbes Investment Guru Commentary on NVO
RSS News Feed on NVO
|
A D V E R T I S E M E N T
|